Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.
about
Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer.The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
P2860
Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@ast
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@en
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@nl
type
label
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@ast
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@en
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@nl
prefLabel
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@ast
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@en
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@nl
P2093
P2860
P356
P1476
Evidence-based guideline recom ...... rmediate-risk prostate cancer.
@en
P2093
D Andrew Loblaw
Genitourinary Cancer Disease Site Group
George Rodrigues
Joseph L Chin
Michael Brundage
Xiaomei Yao
P2860
P304
P356
10.5489/CUAJ.478
P577
2013-05-01T00:00:00Z